In 2024, Novo Nordisk plans to boost its current investments, aiming to allocate
USD 6.8 billion towards production, a significant increase from the previous
year's investment of USD 3.9 billion*.
Bagsværd, Denmark, 24 June 2024 - Novo Nordisk today announced plans to invest
4.1 billion US dollars (approx 27 billion Danish kroner) to build a second fill
and finishing manufacturing facility in Clayton, North Carolina, and grow its
ability to produce current and future injectable treatments for people with
obesity and other serious chronic diseases.
Marking one of the largest manufacturing investments in Novo Nordisk's history,
the expansion will add 1.4 million square feet of production space for aseptic
manufacturing and finished production processes, doubling the combined square
footage of all three of the company's existing facilities in North Carolina. It
will also add 1,000 new jobs, besides the nearly 2,500 Novo Nordisk employees
already working in the region, a central hub for innovation and biotechnology in
the United States.
"It took us a century to reach 40 million patients, but through this expansion
and continued investment in our global production, we're building Novo Nordisk's
ability to serve millions more people living with serious chronic diseases in
the future," said Lars Fruergaard Jørgensen, president and CEO of Novo Nordisk.
"This is yet another real signal of our efforts to scale up our production to
meet the growing global need for our life-changing medicines and the patients of
tomorrow."
Utilising state-of-the-art technology, roof-top solar panels and innovative
water strategies, the facility is designed in an efficient and environmentally
sustainable way to deliver the highest-quality products to patients around the
world. The goal is to obtain LEED Gold certification, recognised as a standard
of excellence in constructing healthy, efficient, carbon and cost-saving green
buildings.
"Clayton was the first manufacturing site for Novo Nordisk in the US, and this
new, large-scale investment confirms the continued importance of our production
facilities there as cornerstones of our company's growth," said Henrik Wulff,
executive vice president, Product Supply, Quality & IT, Novo Nordisk. "For
decades, we have partnered to foster a well-trained, dedicated and diverse local
workforce in North Carolina. In Clayton and across our global manufacturing
sites, we are driven by one purpose: to deliver more for the millions of people
living with chronic diseases - and this facility will help us achieve just
that."
Early clearing and foundational work are already underway to prepare the 56-acre
facility footprint. Construction will gradually be finalized between 2027 and
2029. Around 2,000 external contractors will be engaged at the height of the
project.
"It's a historic day for Johnston County," said Butch Lawter, Chair of the
Johnston County Board of Commissioners, who, during today's press conference,
announced county grants to further support the expansion project. "Thirty-one
years ago, Novo Nordisk decided to make a new home here in Clayton. Then, in
2016, they announced a new facility right across the street - the single largest
life sciences investment on state record at the time. Today, they're breaking
that record again? with a third facility, 1,000 new jobs and a vote of
confidence in the partnerships we have forged in the community over the
decades."
In 2024, Novo Nordisk will increase actual investments in production and plans
to invest approx USD 6.8 billion (DKK 45 billion) in production compared to
actual investments of USD 3.9 (DKK 26 billion) last year* to increase supply.
Visit novonordisk.com for photos (https://www.novonordisk.com/news-and-
media/media-library.html) and b-roll
(https://www.novonordisk.com/media/broadcast-room.html) supporting this press
release.
About Novo Nordisk manufacturing
Novo Nordisk has a global manufacturing setup with five strategic production
sites located in Denmark, US, France,
Brazil and China. All Novo Nordisk's medicines are manufactured at these sites
and subsequently distributed to patients around the globe. This includes
producing almost half of the world's insulin, GLP-1 medicines for the treatment
of diabetes and obesity and medicines to treat rare diseases such as haemophilia
and growth disorders. Novo Nordisk's manufacturing unit has almost 20,000
employees who are dedicated to delivering the highest quality to patients
globally in an efficient and environmentally sustainable way.
About Novo Nordisk
Novo Nordisk is a leading global healthcare company, founded in 1923 and
headquartered in Denmark. Our purpose is to drive change to defeat serious
chronic diseases, built upon our heritage in diabetes. We do so by pioneering
scientific breakthroughs, expanding access to our medicines, and working to
prevent and ultimately cure disease. Novo Nordisk employs about 66,000 people in
80 countries and markets its products in around 170 countries. For more
information, visit novonordisk.com (http://www.novonordisk.com), Facebook
(http://www.facebook.com/novonordisk), Instagram
(https://www.instagram.com/novonordisk), X (http://www.twitter.com/novonordisk),
LinkedIn (http://www.linkedin.com/company/novo-nordisk) and YouTube
(http://www.Youtube.com/novonordisk).
Contacts for further information
Media:

 Ambre James-Brown                      Liz Skrbkova (US)
 +45 3079 9289                          +1 609 917 0632
 abmo@novonordisk.com                   lzsk@novonordisk.com
 (mailto:abmo@novonordisk.com)          (mailto:lzsk@novonordisk.com)

Investors:

 Jacob Martin Wiborg Rode               David Heiberg Landsted
 +45 3075 5956                          +45 3077 6915
 jrde@novonordisk.com                   dhel@novonordisk.com
 (mailto:jrde@novonordisk.com)          (mailto:dhel@novonordisk.com)
 Sina Meyer                             Frederik Taylor Pitter
 +45 3079 6656                          +45 3075 8259
 azey@novonordisk.com                   fptr@novonordisk.com
 (mailto:azey@novonordisk.com)          (mailto:fptr@novonordisk.com)
 Ida Melvold Gjøsund                    Mark Joseph Root (US)
 +45 3077 5649                          +1 848 213 3219
                                        mjhr@novonordisk.com
                                        (mailto:mjhr@novonordisk.com)

*not including acquisitions
Â